Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

This trial is testing whether adding immune checkpoint inhibitors (a type of immunotherapy) to standard chemotherapy before surgery can improve outcomes in people with locally advanced colorectal cancer (stage II or III, cancer that has not spread to distant organs). It compares chemotherapy alone versus chemotherapy plus immunotherapy as a pre-surgical treatment (called neoadjuvant therapy). **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with stage II or III colorectal adenocarcinoma (confirmed by biopsy) - Your cancer is locally advanced but has not spread to distant organs (no metastases) - You have not had prior chemotherapy or radiation for colorectal cancer - You are in good health (ECOG 0–1) with adequate organ function - Tumor tissue is available for genetic testing (mismatch repair/microsatellite instability) **You may NOT be eligible if...** - Your cancer is not the adenocarcinoma type (e.g., squamous, melanoma, GIST) - Your cancer has spread to distant organs (metastatic disease) - You have had another cancer in the past 5 years (with some exceptions for skin or in situ cancers) - You have significant autoimmune disease or uncontrolled bleeding Talk to your doctor to see if this trial is right for you.